From each FDA label

Can GLP-1s cause allergic reactions?

10 of the 10 current GLP-1 labels carry a warning on allergic reactions. Wegovy's label says: "Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with Wegovy."

Read from each manufacturer's FDA label on DailyMed. The newest revision saying anything on this is Aug 28, 2026.

Word for word

What each label says about allergic reactions

Sentences from each label's warnings and side effect sections. Only cross-references are removed.

Wegovy · Warning: Hypersensitivity Reactions

Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with Wegovy.
If hypersensitivity reactions occur, discontinue use of Wegovy, treat promptly per standard of care, and monitor until signs and symptoms resolve.
Wegovy is contraindicated in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy.

Label revised Jun 18, 2026. DailyMed

Ozempic · Warning: Hypersensitivity Reactions

Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with Ozempic.
If hypersensitivity reactions occur, discontinue use of Ozempic; treat promptly per standard of care, and monitor until signs and symptoms resolve.
Do not use in patients with a previous hypersensitivity to Ozempic.

Label revised Jun 1, 2026. DailyMed

Rybelsus and Ozempic tablets · Warning: Hypersensitivity Reactions

Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with semaglutide tablets.
If hypersensitivity reactions occur, discontinue use of Rybelsus or Ozempic tablets; treat promptly per standard of care and monitor until signs and symptoms resolve.
Rybelsus and Ozempic tablets are contraindicated in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Rybelsus or Ozempic tablets.

Label revised Jan 30, 2026. DailyMed

Zepbound · Warning: Hypersensitivity Reactions

There have been postmarketing reports of serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) in patients treated with tirzepatide.
In a pool of two Zepbound clinical studies for weight reduction (Studies 1 and 2), 0.1% of Zepbound-treated patients had severe hypersensitivity reactions compared to no placebo-treated patients.
Similar rates of severe hypersensitivity reactions were observed in Zepbound clinical trials for weight reduction and in Zepbound trials for OSA.
In a pool of Study 1 and 2, immediate hypersensitivity reactions (within one day after drug administration) occurred in 2.1% of Zepbound-treated patients compared to 0.4% of placebo-treated patients, while non-immediate hypersensitivity reactions occurred in 3.5% of Zepbound-treated patients compared to 2.7% of placebo-treated patients.

Label revised Aug 28, 2026. DailyMed

Mounjaro · Warning: Hypersensitivity Reactions

Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with Mounjaro.
If hypersensitivity reactions occur, discontinue use of Mounjaro; treat promptly per standard of care, and monitor until signs and symptoms resolve.
Do not use in patients with a previous serious hypersensitivity reaction to tirzepatide or any of the excipients in Mounjaro.
Hypersensitivity reactions have been reported with Mounjaro in the pool of placebo-controlled trials in adults, sometimes severe (e.g., urticaria and eczema); hypersensitivity reactions were reported in 3.2% of Mounjaro-treated patients compared to 1.7% of placebo-treated patients.

Label revised Aug 27, 2026. DailyMed

Foundayo · Warning: Hypersensitivity Reactions

Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists.
If hypersensitivity reactions occur, advise the patient to promptly seek medical attention and discontinue use of Foundayo.
Foundayo is contraindicated in patients with a prior serious hypersensitivity reaction to orforglipron or to any of the excipients in Foundayo.
In a pool of Trials 1 and 2, hypersensitivity reactions, including anaphylactic reaction, occurred in 0.5% of Foundayo-treated patients compared to 0.3% of placebo-treated patients.

Label revised Jul 29, 2026. DailyMed

Trulicity · Warning: Hypersensitivity Reactions

There have been postmarketing reports of serious hypersensitivity reactions including anaphylactic reactions and angioedema in patients treated with Trulicity.
If a hypersensitivity reaction occurs, discontinue Trulicity; treat promptly per standard of care, and monitor until signs and symptoms resolve.
Trulicity is contraindicated in patients with a previous serious hypersensitivity reaction to dulaglutide or to any of the components of Trulicity.
Systemic hypersensitivity adverse reactions, sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling), occurred in 0.5% of adult patients on Trulicity in clinical studies.

Label revised Jun 16, 2026. DailyMed

Saxenda · Warning: Hypersensitivity Reactions

There have been reports of serious hypersensitivity reactions (e.g., anaphylactic reactions and angioedema) in patients treated with Saxenda.
If a hypersensitivity reaction occurs, the patient should discontinue Saxenda and other suspect medications and promptly seek medical advice.
Anaphylaxis and angioedema have been reported with other GLP-1 receptor agonists.
Anaphylactic reactions, asthma, bronchial hyperreactivity, bronchospasm, oropharyngeal swelling, facial swelling, angioedema, pharyngeal edema, type IV hypersensitivity reactions have been reported in patients treated with liraglutide in clinical trials.

Label revised Feb 25, 2026. DailyMed

Victoza · Warning: Hypersensitivity Reactions

There have been postmarketing reports of serious hypersensitivity reactions (e.g., anaphylactic reactions and angioedema) in patients treated with Victoza.
If a hypersensitivity reaction occurs, discontinue Victoza; treat promptly per standard of care, and monitor until signs and symptoms resolve.
Anaphylaxis and angioedema have been reported with other GLP-1 receptor agonists.

Label revised Oct 14, 2025. DailyMed

Byetta · Warning: Hypersensitivity

There have been postmarketing reports of serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) in patients treated with Byetta.
If a hypersensitivity reaction occurs, the patient should discontinue Byetta and other suspect medications and promptly seek medical advice.
Inform and closely monitor patients with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist for allergic reactions, because it is unknown whether such patients will be predisposed to anaphylaxis with Byetta.
Two serious adverse events (chest pain and chronic hypersensitivity pneumonitis) were reported in the Byetta arm.

Label revised Sep 2, 2025. DailyMed

Not from trials

Reports to FDA about allergic reactions

Counts of voluntary reports from patients and doctors. They cannot show that a medicine caused anything and cannot give a rate, and a brand used by more people draws more reports.

Medicine	Reports naming	All reports on it
Mounjaro	Hypersensitivity: 603 · Urticaria: 473 · Anaphylactic reaction: 200 · Angioedema: 152	97,440
Zepbound	Hypersensitivity: 552 · Urticaria: 399 · Anaphylactic reaction: 82 · Angioedema: 21	80,835
Trulicity	Hypersensitivity: 438 · Urticaria: 403 · Anaphylactic reaction: 82 · Angioedema: 75	87,279
Ozempic	Hypersensitivity: 396 · Urticaria: 364 · Anaphylactic reaction: 89 · Angioedema: 72	70,863
Byetta	Urticaria: 383 · Hypersensitivity: 297 · Anaphylactic reaction: 60 · Angioedema: 45	52,087
Victoza	Urticaria: 308 · Hypersensitivity: 266 · Angioedema: 72 · Anaphylactic reaction: 58	41,462
Wegovy	Urticaria: 128 · Hypersensitivity: 118 · Anaphylactic reaction: 34 · Angioedema: 26	25,993
Saxenda	Urticaria: 68 · Hypersensitivity: 45 · Anaphylactic reaction: 16 · Angioedema: 14	7,270
Rybelsus and Ozempic tablets	Hypersensitivity: 51 · Urticaria: 51 · Anaphylactic reaction: 20 · Angioedema: 16	7,758
Foundayo	Hypersensitivity: 29 · Urticaria: 13 · Angioedema: 4 · Anaphylactic reaction: 2	3,050

Counted through openFDA from FDA's Adverse Event Reporting System, refreshed weekly. One report can name several terms.

Updated automatically

Latest FDA label updates

Aug 28, 2026FDA labelFDA label updated: Zepbound (Eli Lilly and Company), effective 2026-08-28
Aug 27, 2026FDA labelFDA label updated: Mounjaro (Eli Lilly and Company), effective 2026-08-27
Jul 29, 2026FDA labelFDA label updated: Foundayo (Eli Lilly and Company), effective 2026-07-29
Jul 27, 2026FDA labelFDA label updated: Liraglutide (Meitheal Pharmaceuticals Inc.), effective 2026-07-27
Jun 24, 2026FDA labelFDA label updated: Liraglutide (NorthStar Rx LLC), effective 2026-06-24

Written from each source's own record as it changes. Every change on GLPcompare

Questions

Allergic reactions on a GLP-1: common questions

Can Wegovy cause allergic reactions?

Its FDA label: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with Wegovy. If hypersensitivity reactions occur, discontinue use of Wegovy, treat promptly per standard of care, and monitor until signs and symptoms resolve.

Can Ozempic cause allergic reactions?

Its FDA label: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with Ozempic. If hypersensitivity reactions occur, discontinue use of Ozempic; treat promptly per standard of care, and monitor until signs and symptoms resolve.

Can Rybelsus cause allergic reactions?

Its FDA label: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with semaglutide tablets. If hypersensitivity reactions occur, discontinue use of Rybelsus or Ozempic tablets; treat promptly per standard of care and monitor until signs and symptoms resolve.

Can Zepbound cause allergic reactions?

Its FDA label: There have been postmarketing reports of serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) in patients treated with tirzepatide. In a pool of two Zepbound clinical studies for weight reduction (Studies 1 and 2), 0.1% of Zepbound-treated patients had severe hypersensitivity reactions compared to no placebo-treated patients.

Can Mounjaro cause allergic reactions?

Its FDA label: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with Mounjaro. If hypersensitivity reactions occur, discontinue use of Mounjaro; treat promptly per standard of care, and monitor until signs and symptoms resolve.

Can Foundayo cause allergic reactions?

Its FDA label: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists. If hypersensitivity reactions occur, advise the patient to promptly seek medical attention and discontinue use of Foundayo.

Can Trulicity cause allergic reactions?

Its FDA label: There have been postmarketing reports of serious hypersensitivity reactions including anaphylactic reactions and angioedema in patients treated with Trulicity. If a hypersensitivity reaction occurs, discontinue Trulicity; treat promptly per standard of care, and monitor until signs and symptoms resolve.

Can Saxenda cause allergic reactions?

Its FDA label: There have been reports of serious hypersensitivity reactions (e.g., anaphylactic reactions and angioedema) in patients treated with Saxenda. If a hypersensitivity reaction occurs, the patient should discontinue Saxenda and other suspect medications and promptly seek medical advice.

Can Victoza cause allergic reactions?

Its FDA label: There have been postmarketing reports of serious hypersensitivity reactions (e.g., anaphylactic reactions and angioedema) in patients treated with Victoza. If a hypersensitivity reaction occurs, discontinue Victoza; treat promptly per standard of care, and monitor until signs and symptoms resolve.

Trial rates describe groups, not what one person will feel. Talk to your clinician before starting, stopping or changing a medicine.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.